GILD · Gilead Sciences, Inc.
$127.882026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$138
+7.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($126 · $212) Analysts Range ($122 · $180) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $27.1B | — | 30.9% | 45.0% | $4.6B | −$5.8B | −$1.2B | 6.0% | — | 8.5% | $53.9B | $4.52 | — |
| 2024.Q4 | $27.1B | 0.0% | 30.9% | 30.6% | $5.8B | −$4.6B | $1.2B | 6.3% | — | 11.0% | $51.8B | $4.52 | — |
| 2025.Q1 | $28.8B | 6.0% | 6.4% | 12.6% | $1.6B | −$1.4B | $156MM | 5.9% | — | 3.0% | $54.0B | $0.38 | — |
| 2025.Q4 | $28.8B | 0.0% | 6.4% | 13.1% | $1.6B | −$4.0B | −$2.4B | 6.0% | — | 2.9% | $54.4B | $0.38 | — |
| 2026.Q1 | $29.7B | 3.4% | 42.1% | 14.1% | $10.8B | −$3.5B | $7.3B | 5.6% | — | 20.0% | $53.4B | $7.35 | 12.8 |
| italics below = DCF projection · 10yr Rev CAGR: 5.1% |
| 2027.Q1 | $30.9B | +4.0% | 46.4% | 14.7% | $12.2B | −$2.2B | $10.1B | 5.9% | $9.5B | 22.5% | $55.5B | $8.05 | 15.9 |
| 2028.Q1 | $32.8B | +6.2% | 44.0% | 15.3% | $12.2B | −$3.6B | $8.6B | 6.2% | $7.7B | 21.3% | $59.1B | $8.18 | 15.6 |
| 2029.Q1 | $34.8B | +6.1% | 41.6% | 15.9% | $12.2B | −$3.8B | $8.3B | 6.5% | $7.0B | 20.0% | $63.0B | $8.29 | 15.4 |
| 2030.Q1 | $37.3B | +7.1% | 39.2% | 16.4% | $12.2B | −$4.9B | $7.4B | 6.7% | $5.8B | 18.7% | $67.8B | $8.47 | 15.1 |
| 2031.Q1 | $39.2B | +5.2% | 34.5% | 17.0% | $11.2B | −$3.9B | $7.3B | 7.0% | $5.3B | 16.1% | $71.8B | $8.12 | 15.7 |
|
| Term. Yr+ | $51.0B | 4.1% | 34.5% | 20.0% | $14.1B | −$4.4B | $9.7B | 8.6% | $107.9B | 13.1% | — | — | — |
Active scenario IV: $138 (+7.7% vs market)